Carolina Jaramillo Oquendo

Carolina Jaramillo Oquendo

Auto-generated profile, based on publicly available information

Carolina Jaramillo Oquendo

School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2026 in European Journal of Human Genetics
Verified
Journal Article
Open access
COCarolina Jaramillo Oquendo
Carolina Jaramillo Oquendo
FFFederico Ferraro
Federico Ferraro
HWHtoo A. Wai
Htoo A. Wai
HFHeather Ferrao
Heather Ferrao
HLHerma van der Linde
Herma van der Linde
DBDiana Baralle
Diana Baralle
Splice-disrupting variants are estimated to account for one-third of disease-causing variants, yet many remain underrepresented in clinical databases due to limitations in detecting splicing changes beyond canonical splice sites. Short-read RNA sequencing (RNA-seq) has proved to be a valuable complement in clinical practice to address this gap, however, the added value of long-read RNA-seq is unclear. We evaluated the potential of PacBio long-read RNA-seq to detect pathogenic splicing events in rare disorders, comparing its performance to short-read RNA-seq. Participants from the UK ( n = 23) and the Netherlands ( n = 2) with suspected splice-altering variants underwent long-read RNA-seq following the Kinnex full-length RNA protocol. HiFi reads from the Revio instrument were processed using the Read Segmentation and Iso-Seq workflow and then classified and filtered using Pigeon. Detection of disease genes was comparable with short reads, with fibroblast capturing more transcripts overall. Novel isoforms accounted for ~14% of detected transcripts in both tissues, increasing following cycloheximide treatment in fibroblasts and decreasing following globin depletion in blood. Transcript abundance estimates showed strong concordance between short- and long-read platforms (Pearson r = 0.86 and 0.61 in blood and fibroblasts, respectively). LRS captured 21 confirmed known events, and revealed additional transcript-level effects in eight cases. This included intron retention, multiple exon skipping, leaky splicing, variant phasing, and isoform switching. These results demonstrate that long-read RNA-seq enhances detection and interpretation of clinically relevant splicing events, supporting its integration into diagnostic workflows for rare diseases.

23 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JLJenny Lord
Jenny Lord
APAlistair T Pagnamenta
Alistair T Pagnamenta
LVLetizia Vestito
Letizia Vestito
SWSusan Walker
Susan Walker
COCarolina Jaramillo Oquendo
Carolina Jaramillo Oquendo
DBDiana Baralle
Diana Baralle
RNA sequencing (RNA-Seq) is increasingly used alongside exome and genome sequencing to identify causal variants underlying rare Mendelian disorders. We present short-read RNA-Seq data from 5,412 individuals with a diverse range of rare disorders recruited to Genomics England’s 100,000 Genomes Project. We show that the proportion of genes from gene panels applied to different disorders which are well captured (transcripts per million (TPM) ≥ 5) from blood RNA varies widely, highlighting differences in applicability across disorder types. Using OUTRIDER and FRASER2 to identify gene expression and splicing outliers respectively, we identify at least one outlier event in a disorder relevant gene in 20% of the cohort. To prioritise likely diagnostic candidates, we apply multiple strategies including focussing on outlier events in known haploinsufficient genes (n=78), integrating outliers with structural variant calls (n=19), and using strategies integrating phenotypic presentation (Exomiser, n=39). We present a series of candidate diagnoses involving diverse variant types and disease mechanisms, demonstrating the broad utility of RNA-Seq in identifying and prioritising diagnostic candidates in individuals with a variety of different rare conditions and no known genetic diagnosis. Our findings demonstrate that blood-based RNA-Seq can deliver clinically relevant findings across a broad range of rare disorders.

27 May 2026 in Blood Advances
Verified
Journal Article
Open access
HPHelen Parker
Helen Parker
Amatta MirandariAmatta Mirandari
Amatta Mirandari
BSBen Stevens
Ben Stevens
CJCarolina Jaramillo-Oquendo
Carolina Jaramillo-Oquendo
MDMartí Duran-Ferrer
Martí Duran-Ferrer
JSJonathan Strefford
Jonathan Strefford
Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy with notable genetic, epigenetic, and clinical heterogeneity. This study utilized coding and non-coding sequencing (n=74), including whole-genome sequencing (WGS) on 24 paired tumour-normal samples, targeted sequencing (n=55) and DNA methylation in 126 cases to characterize the disease. From WGS, we identified recurrent, predominantly clonal, coding mutations in KLF2 (50%), KMT2D (25%) and NOTCH2 (25%), alongside rare mutations in FLNC (8%), novel mutations in FAM135B (17%) and non-coding mutational hotspots in BCL6, PAX5 and BACH2, linked to aberrant somatic hypermutation. At least one non-coding hotspot was detected in 69% of cases. Copy-number aberrations (CNAs) were present in 73% of cases, including del(7q) (27%), gain(3q) (17%) and trisomy 12 (13%). DNA methylation profiling revealed two epigenetic subgroups: SMZL-HR (high-risk, n=67) and SMZL-LR (low-risk, n=59). SMZL-HR was associated with adverse features such as female sex, IGHV1-2*04 usage, KLF2 mutations, del(7q), shorter telomeres, and elevated epiCMIT scores. Transcriptomic analysis highlighted enhanced cell proliferation in SMZL-HR, with enrichment of E2F and G2M checkpoint pathways and epigenetic regulation via EZH2. SMZL-HR patients had significantly shorter time to first treatment (TTFT) (HR: 1.9, p=.003) and reduced overall survival (HR: 2.5, p=.039): 85% of SMZL-HR patients required treatment and showed a higher frequency of transformation (p=.007) and mortality (p<.001). Multivariate analysis confirmed SMZL-HR as an independent predictor of shorter TTFT (HR: 2.4, p=.001). These findings demonstrate the role of DNA methylation and molecular profiling in SMZL risk stratification.

8 July 2023 in medRxiv
Verified
Preprint
Open access
PDF file
COCarolina Jaramillo Oquendo
Carolina Jaramillo Oquendo
HWHtoo A Wai
Htoo A Wai
WRWill Rich
Will Rich
DBDavid J. Bunyan
David J. Bunyan
NTN. Simon Thomas
N. Simon Thomas
DBDiana Baralle
Diana Baralle
Background: RNA-sequencing is increasingly being used as a complementary tool to DNA sequencing in diagnostics where DNA analysis has been uninformative. RNA-sequencing allows us to identify alternative splicing and aberrant gene expression allowing for improved interpretation of variants of unknown significance (VUS). Additionally, RNA-sequencing provides the opportunity not only to look at the splicing effects of known VUSs but also to scan the transcriptome for abnormal splicing events and expression abnormalities in other relevant genes that may be the cause of a patient’s phenotype. Methods: Using RNA from patient blood, we have systematically assessed transcriptomic profiles of 87 patients with suspected Mendelian disorders, 38% of which did not have a candidate sequence variant. Cases with VUSs and known events were assessed first followed by assessment of cases with no VUS. Each VUS was visually inspected using the Integrative Genomics Viewer (IGV) to search for splicing abnormalities. Once aberrant splicing was identified in cases with VUS, multiple open-source alternative splicing tools (MAJIQ, rMATS-turbo, FRASER2 and LeafCutterMD) were used to investigate if they would identify what was observed in IGV. Expression outliers were detected using OUTRIDER. To find diagnoses in cases without a VUS or gene of interest, two separate strategies were used. The first was a genotype to phenotype approach using variant calls obtained from the RNA-sequencing and overlapping those calls with results from splicing tools. The second strategy involved using phenotype information available to filter results from splicing tools. Results: Using RNA-sequencing only, we were able to assess 71% of VUSs and detect aberrant splicing in 14/48 patients with a VUS. Furthermore, we identified four new diagnoses by detecting novel aberrant splicing events in patients with no candidate sequence variants from prior genomic DNA testing (n=33) or those in which the candidate VUS did not affect splicing (n=23) and identified one additional diagnosis through detection of skewed X-inactivation. Conclusion: We demonstrate the identification of novel diagnoses using an RNA-sequencing first approach in patients without candidate VUSs. Furthermore, we demonstrate the utility of blood-based RNA analysis in improving diagnostic yields and highlight optimal approaches for such analysis.

25 July 2025 in Research Square
Verified
Preprint
Open access
PDF file
COCarolina Jaramillo Oquendo
Carolina Jaramillo Oquendo
FFFederico Ferraro
Federico Ferraro
HWHtoo Wai
Htoo Wai
HFHeather Ferrao
Heather Ferrao
HLHerma van der Linde
Herma van der Linde
DBDiana Baralle
Diana Baralle
Splice-disrupting variants are estimated to account for one-third of disease-causing variants, yet many remain underrepresented in clinical databases due to limitations in detecting splicing changes beyond canonical splice sites. Short-read RNA sequencing (RNA-seq) has proved to be a valuable complement in clinical practice to address this gap, however, the added value of long-read RNA-seq is unclear. Here, we aimed to assess the clinical utility of PacBio long-read RNA-seq to characterise pathogenic aberrant splicing in rare disorders compared to short-read RNA-seq. Participants from the UK and the Netherlands with suspected splice-altering variants underwent long-read RNA-seq. 28 blood samples and four fibroblast cell lines were sequenced following the Kinnex full-length RNA protocol. Detection of disease genes (OMIM and PanelApp) was comparable with short reads, with fibroblast capturing more transcripts overall. Novel isoforms accounted for ~ 14% of detected transcripts in both tissues, increasing following cycloheximide treatment in fibroblasts and decreasing following goblin depletion in blood. Long-read RNA-seq detected events missed by short-reads including intron retention, multiple exon skipping, differential transcript usage, leaky splicing and variant phasing. In one case long reads revealed that a splice region variant in RPS7 skewed expression toward an unannotated intron 6-retained transcript, likely leading to protein deficiency explaining previous ambiguous results in patient with Diamond-Blackfan anaemia. In another case, we identified a retrotransposon-induced isoform switch in TCOF1 causing Treacher Collins syndrome. Both examples unresolved by short reads. Thereby long-read RNAseq has the potential to improve the detection of clinically relevant transcripts when used in a clinical setting.

12 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MRMwenda R. Rintari
Mwenda R. Rintari
VCV. Kartik Chundru
V. Kartik Chundru
COCarolina J. Oquendo
Carolina J. Oquendo
JLJoseph Leslie
Joseph Leslie
APAlistair T. Pagnamenta
Alistair T. Pagnamenta
CWCaroline F. Wright
Caroline F. Wright
Missense variant pathogenicity is usually interpreted according to the predicted effect on the protein via polypeptide alterations. But missense variants can also cause disease by disrupting RNA splicing, here defined as missense spliceogenic variants (MSVs). Although splice prediction is increasingly incorporated into variant classification pipelines, it is not a standardised process, so the scale and clinical relevance of MSVs remains poorly defined. We integrated whole-genome sequencing and circulating proteomic data from ∼50,000 UK Biobank participants to characterise MSVs using ∼8.3 million missense variants. We found that 2.7% of missense variants are predicted to alter splicing (SpliceAIΔ ≥ 0.2), comparable with synonymous variants (2.8%). Notably, 57% had benign/neutral AlphaMissense and REVEL scores (<0.34 and <0.5 respectively), rising to 85.2% in intrinsically disordered regions, indicating that many MSVs would not be prioritised by protein-centric predictors. MSVs were associated with reduced circulating levels of the cognate protein, approaching the effects of predicted loss-of-function variants. Analysis of raw SpliceAI scores revealed that events where novel cryptic sites outscored canonical sites resulted in the largest protein depletion, particularly when a premature frameshift was introduced. Validation of 14 predicted MSVs of uncertain significance in a clinical cohort provided strong pathogenic/likely pathogenic evidence, and screening unsolved cases from the 100,000 Genomes Project identified two novel candidate diagnostic MSVs. These findings establish the scale and functional consequences of MSVs, and demonstrate that RNA-centric interpretation can reveal clinically-relevant loss-of-function mechanisms missed by protein-centric missense variant interpretation.